Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nepafenac + sodium carboxymethylcellulose
- Development stage
- Phase 4
- Lead developer
- Instituto de Oftalmologia Fundacion Conde de Valenciana
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
This is an investigational combination therapy consisting of nepafenac, a nonsteroidal anti-inflammatory drug (NSAID), and sodium carboxymethylcellulose, an ocular lubricant. Developed by the Instituto de Oftalmología Fundación Conde de Valenciana in Mexico, the combination is being evaluated for the treatment of epiphora (excessive tearing) resulting from lacrimal punctum stenosis (narrowing of the tear duct opening). Nepafenac acts as a prodrug that is converted into amfenac, which inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing inflammation that may contribute to punctal narrowing. The lubricant component, sodium carboxymethylcellulose, helps stabilize the tear film and reduce ocular surface irritation, which is often associated with chronic tearing and ductal stenosis.
- Other names
- nepafenac + lubricantnepafenac + carboxymethylcellulose
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on nepafenac + sodium carboxymethylcellulose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nepafenac + sodium carboxymethylcellulose.